UroGen Pharma Balance Sheet Health
Financial Health criteria checks 4/6
UroGen Pharma has a total shareholder equity of $25.5M and total debt of $121.7M, which brings its debt-to-equity ratio to 477%. Its total assets and total liabilities are $301.9M and $276.4M respectively.
Key information
477.0%
Debt to equity ratio
US$121.71m
Debt
Interest coverage ratio | n/a |
Cash | US$249.58m |
Equity | US$25.52m |
Total liabilities | US$276.43m |
Total assets | US$301.94m |
Recent financial health updates
Recent updates
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?
Nov 18UroGen Pharma: There Is Some Potential Here
Aug 28UroGen: Q3 NDA Opens Hefty Revenue Opportunity
Jun 17UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jun 14UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Apr 09UroGen: All Eyes On UGN-102
Mar 18UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Mar 17UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 18UroGen gets FDA nod for extending duration of Jelmyto admixture
Sep 28Financial Position Analysis
Short Term Liabilities: URGN's short term assets ($295.1M) exceed its short term liabilities ($32.8M).
Long Term Liabilities: URGN's short term assets ($295.1M) exceed its long term liabilities ($243.6M).
Debt to Equity History and Analysis
Debt Level: URGN has more cash than its total debt.
Reducing Debt: URGN's debt to equity ratio has increased from 0% to 477% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: URGN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if URGN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.